Hematology Reports

4 pages, 393 KiB

Open AccessArticle

Patient Compliance with Deep Vein Thrombosis Prophylaxis after Total Hip and Total Knee Arthroplasty

by Daniel H. Wiznia, Nishwant Swami, Jenny Nguyen, Eric Musonza, Chris Lynch, David Gibson and Richard Pelker

Hematol. Rep. 2019, 11(2), 7914; https://doi.org/10.4081/hr.2019.7914 - 17 Jun 2019

Cited by 7 | Viewed by 904

Abstract

Even though the Centers for Medicare and Medicaid Services is penalizing hospitals for readmissions, and postoperative prophylaxis has demonstrated reduced complications associated with deep vein thrombosis (DVT), few studies have examined patient compliance with (DVT) prophylaxis at home. A survey querying DVT prophylaxis [...] Read more.

Even though the Centers for Medicare and Medicaid Services is penalizing hospitals for readmissions, and postoperative prophylaxis has demonstrated reduced complications associated with deep vein thrombosis (DVT), few studies have examined patient compliance with (DVT) prophylaxis at home. A survey querying DVT prophylaxis management and adherence was administered to patients who were within the one to three-month postoperative period after a total knee or total hip replacement. A total of 103 patients completed the survey. A considerable number of patients (17.0%) were non-adherent to DVT prophylaxis. Patients had a lower understanding of the side effects of their DVT prophylaxis, with 30% responding that they had a poor to simple understanding. There is a high rate of non-compliance and there is a poor understanding of complications related to venous thromboembolism prophylaxis. As the population undergoing arthroplasties grows, this study demonstrates the importance of investigating the role of medication adherence in the rate of postoperative DVT. Full article

3 pages, 306 KiB

Open AccessCase Report

B-Cell Acute Lymphoblastic Leukemia as a Secondary Malignancy Following Diffuse Large B-Cell Lymphoma

by Daria Gaut, Anthony Bejjani, Joshua Sasine and Gary Schiller

Hematol. Rep. 2019, 11(2), 8100; https://doi.org/10.4081/hr.2019.8100 - 14 Jun 2019

Viewed by 550

Abstract

Secondary acute lymphoblastic leukemia (ALL) is a rare disease that has not been well characterized compared with secondary myelodysplastic syndrome or secondary acute myeloid leukemia. We present a report of two patients who developed ALL following complete remission of diffuse large B-cell lymphoma [...] Read more.

Secondary acute lymphoblastic leukemia (ALL) is a rare disease that has not been well characterized compared with secondary myelodysplastic syndrome or secondary acute myeloid leukemia. We present a report of two patients who developed ALL following complete remission of diffuse large B-cell lymphoma (DLBCL). The first case is more consistent with a therapy-related ALL as a PCR analysis of bone marrow aspirate revealed a distinct clone and the mixed-lineage leukemia gene rearrangement, commonly associated with exposure to topoisomerase II inhibitors. The second case is more consistent with clonal evolution given positive MYC and BCL2 fusion signals in the original diagnosis of DLBCL and the secondary ALL. Full article

4 pages, 400 KiB

Open AccessArticle

Health Status and Quality of Life in Patients with Severe Hemophilia A: A Cross-Sectional Survey

by Majid Davari, Zahra Gharibnaseri, Roya Ravanbod and Abolfazl Sadeghi

Hematol. Rep. 2019, 11(2), 7894; https://doi.org/10.4081/hr.2019.7894 - 14 Jun 2019

Cited by 16 | Viewed by 848

Abstract

Among different groups of hemophiliacs, those suffering from Severe Hemophilia A (SHA) are most vulnerable to the complications of the disease. This study investigated the Health-Related Quality of Life (HR-QoL) among adult patients with SHA. A cross-sectional study was designed to gather demographic [...] Read more.

Among different groups of hemophiliacs, those suffering from Severe Hemophilia A (SHA) are most vulnerable to the complications of the disease. This study investigated the Health-Related Quality of Life (HR-QoL) among adult patients with SHA. A cross-sectional study was designed to gather demographic and clinical information from adult patients with SHA. Patients with inhibitors were excluded. The remaining were asked to complete the HR-QoL questionnaire after being examined for joint health using the Hemophilia Joint HealthScore (HJHS). The HR-QoL and joint conditions were measured in 38 patients. The mean EQ-5D value scores were 0.46 (SD = 0.23) while the mean Visual Analogous Scale score was 50 (SD = 18.7). The clinical examination of patients indicated that the HJHS were as follows: eight patients had a score of 55–75, 12 patients had a score of 40–55, 7 of them (25–40) and 11 patients had a score of 10–25. The results obtained from this study showed that HR-QoL in hemophilia patients was considerably low. Pain, anxiety/depression, and motion limitations were the main causes of the disutility for these patients respectively. Full article

5 pages, 379 KiB

Open AccessArticle

Implications of Intrachromosomal Amplification of Chromosome 21 on Outcome in Pediatric Acute Lymphoblastic Leukemia: Does It Affect Our Patients Too?

by Suleimman Al-Sweedan and Rahaf Altahan

Hematol. Rep. 2019, 11(2), 7826; https://doi.org/10.4081/hr.2019.7826 - 14 Jun 2019

Cited by 1 | Viewed by 496

Abstract

Intrachromosomal amplification (iAMP) of chromosome 21 entity is associated with a dismal outcome in B cell Acute Lymphoblastic Leukemia (B-ALL). This cytogenetic abnormality is caused by a novel mechanism; breakage-fusion-bridge cycles followed by chromothripsis along with major gross rearrangements in chromosome 21.Charts of [...] Read more.

Intrachromosomal amplification (iAMP) of chromosome 21 entity is associated with a dismal outcome in B cell Acute Lymphoblastic Leukemia (B-ALL). This cytogenetic abnormality is caused by a novel mechanism; breakage-fusion-bridge cycles followed by chromothripsis along with major gross rearrangements in chromosome 21.Charts of B-ALL diagnosed at King Faisal Specialist Hospital and Research Center between 2005 and 2015 were reviewed.iAMP is a rare entity occurring at around 2.4% of all pediatrics B-ALL. No statistically significant difference was found among patients with iAMP21, patients with extra copies of 21 and other patients with B-ALL. The reported adverse prognostic effect of iAMP21 could be due to other coexistent adverse factors, including older age at the time of diagnosis. The most common associated abnormality in our population in addition to the hyperdiploidy was ETV6/RUNX1. Full article

2 pages, 348 KiB

Open AccessBrief Report

Availability of All-Trans Retinoic Acid and Support Systems for Management of Acute Promyelocytic Leukemia in Michigan and Louisiana, USA

by Sheldon L. Bolds, Shruthi M.K. Hassan, Catherine R. Caprara, Stephanie Debragga, Kathryn S. Simon, Prachi Karkhanis, Arpita Gandhi, Anand P. Jillella and Vamsi Kota

Hematol. Rep. 2019, 11(2), 7896; https://doi.org/10.4081/hr.2019.7896 - 23 May 2019

Cited by 2 | Viewed by 348

Abstract

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia with high induction mortality in the general population despite evidence of high cure rates in the clinical trials. Aggressive supportive care is essential for ideal management of these patients. We conducted a [...] Read more.

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia with high induction mortality in the general population despite evidence of high cure rates in the clinical trials. Aggressive supportive care is essential for ideal management of these patients. We conducted a survey to collect data on these important issues required for successful treatment/outcome of APL patients from two states (Michigan and Louisiana) due to their low one-year survival rate among the Surveillance, Epidemiology, and End Results registries. All eligible hospitals (253) were obtained from the Data Medicare online directory. Availability of ATRA, formulary process to obtain it, blood back availability and established treatment protocols for the management of APL patients were queried. Since most of the hospitals surveyed do not have a treatment protocol, we believe that outcome could be improved if a standardized and simplified set of treatment and supportive care guidelines are developed for all hospitals treating APL. Full article

Journal Menu

Journal Browser

Hematol. Rep., Volume 11, Issue 2 (May 2019) – 5 articles

Further Information

Guidelines

MDPI Initiatives

Follow MDPI